Pacific Biosciences: Q4 Earnings Insights

Pacific Biosciences (NASDAQ:PACB) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:05 PM. Here’s what…

Pacific Biosciences (NASDAQ:PACB) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

Pacific Biosciences beat estimated earnings by 3.57%, reporting an EPS of $-0.27 versus an estimate of $-0.28.

Revenue was up $31.00 million from the same period last year.

Past Earnings Performance

Last quarter the company beat on EPS by $0.05 which was followed by a 13.08% drop in the share price the next day.

Here’s a look at Pacific Biosciences’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate -0.32 -0.32 -0.33 -0.36
EPS Actual -0.27 -0.26 -0.31 -0.35
Revenue Estimate 48.76M 40.30M 34.38M 26.24M
Revenue Actual 55.69M 47.57M 38.90M 27.35M

To track all earnings releases for Pacific Biosciences visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY

Braxia Scientific Corp., (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, announced the filing of its financial statements and management discussion and analysis for the

BRAXF